Navigostics AG

Navigostics develops novel and highly efficient tumour analyses and algorithms to revolutionise personalised cancer diagnostics. The company produces diagnostic tests for various tumour indications that support treatment decisions for immunotherapies. To this end, Navignostics uses highly multiplexed imaging tissue analysis methods, providing single-cell information to characterise tumour and immune cells and their interactions within the tissue. This data offers crucial insights for predicting the success of immunotherapies. Navignostics AG is a spin-off from the University of Zurich founded in 2022.